AML Clinical Trials in Houston, Texas

8 studies are recruiting for aml in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

   This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   5 in total

   Run by

   CERo Therapeutics Holdings, Inc.

   See if you can join NCT06834282 on ClinicalTrials.gov

2. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

3. A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

   This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The University of Texas - MD Anderson Cancer Center, Houston, Texas

   Locations

   26 in total

   Run by

   TScan Therapeutics, Inc.

   See if you can join NCT07702578 on ClinicalTrials.gov

4. A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

   This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with A…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson, Houston, Texas

   Locations

   21 in total

   Run by

   TScan Therapeutics, Inc.

   See if you can join NCT05473910 on ClinicalTrials.gov

5. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Texas Children's Hospital, Houston, Texas

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

6. Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

   This is a phase Ib/II study that aims to investigate the safety, tolerability and explore the efficacy of BCL- XL inhibition in participants with high-risk AML.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT MD Anderson, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07508982 on ClinicalTrials.gov

7. A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

   The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell transplant.

   Stage

   Phase 2

   Ages

   65 to 75

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06973668 on ClinicalTrials.gov

8. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

   Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Texas Children's Hospital/Baylor College of Medicine, Houston, Texas

   Locations

   31 in total

   Run by

   Therapeutic Advances in Childhood Leukemia Consortium

   See if you can join NCT05476770 on ClinicalTrials.gov